GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same ... Both are risk factors for heart attack and stroke. “Another ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

But, "the mechanism of action is open to speculation," she said. SGLT2 inhibitors have diuretic and anti-inflammatory effects ...

Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) is associated with a lower mortality risk in older patients with advanced chronic kidney disease (CKD), according to data ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's ...

MoA International Fund earns a High Process Pillar rating. The largest contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...